Abstract:Purpose: To determine the risk factors and clinical impact of stent fractures after superficial femoral artery (SFA) stenting. Methods: From May 2009 to June 2012, 171 consecutive patients (mean age 74.5 +/- 7.8, years; 106 men) who presented with SFA stenosis or occlusion in 205 limbs underwent stent implantation in the SFA at a single center. Stent fractures were determined by radiography and classified into types I through V. Loss of patency was assessed by duplex ultrasonography (>2.4 peak systolic velocity ratio) or angiography (percent diameter stenosis >50%). Results: The 12- and 24-month primary patency rates were 49.8% and 43.4%, respectively. Stent fractures occurred in 12.5% and 26.8% per limb (6.6% and 19.4% per stent) at 12 and 24 months, respectively. Primary patency was numerically worse in the stent fracture group but not statistically different from the group without fractures at 2 years. Primary patency for different classes of stent fracture were 30.8% (type I), 50.0% (type II), and 31.3% (type III-V). Hyperlipidemia (p=0.001), TransAtlantic Inter-Society Consensus II classification (p=0.007), chronic total occlusion (CTO; p<0.001), proximal lesion location (p=0.008), lesion calcification (p=0.025), total stent length (p=0.005), stent diameter (p=0.001), and number of stents (p=0.001) were statistically significant predictors of stent fracture. Multivariate analysis showed that CTO (hazard ratio 0.173, 95% confidence interval 0.042 to 0.716, p=0.015) was an independent predictor of stent fracture. Conclusion: Stent fractures occur more frequently in patients with CTOs after treatment of longer stented lesions. Although multivariate analysis showed that CTO was the only independent predictor regardless of stent length or number, the stent fracture rate was numerically higher in the severe calcification and proximal SFA lesion subgroups. Stent fracture did not appear to affect long-term patency rates, but this is yet to be confirmed with further follow-up.

Strut fracture of DES: an increasing problem?

Incidence and Clinical Outcomes of Stent Fractures on the Basis of 6,555 Patients and 16,482 Drug-Eluting Stents From Four Centers.

Drug-eluting Balloons Versus Drug-Eluting Stents for the Management of In-Stent Restenosis: A Meta-Analysis of Randomized and Observational Studies

CRT-200.10 Incidence and Clinical Outcome of Stent Fracture Based on 3411 Patients and 5836 Drug-Eluting Stents Analysis Within One-year after Indexed Stenting Procedures

Incidence of coronary drug-eluting stent fracture: A systematic review and meta-analysis

Intrastent Haematoma After Treatment With A Drug-Eluting Balloon For In-Stent Restenosis: A Case Report

[Long-Term Outcomes and Risk Factors of Ostial/shaft Lesions in Unprotected Left Main Coronary Artery after Percutaneous Coronary Intervention].

Mechanisms and Potential Problems of Drug-Eluting Stent in Preventing Restenosis after Percutaneous Transluminal Angioplasty

In-Stent Restenosis: Achilles’ Heel of Post-PCI Era

Drug-Eluting Stent and Late Stent Thrombosis

Stent fracture is associated with a higher mortality in patients with type-2 diabetes treated by implantation of a second-generation drug-eluting stent

Stent fractures after superficial femoral artery stenting: risk factors and impact on patency.

Research Progress of the Drug-Eluting Stents

The Status and Prospect of Drug-Eluting Stents(DES) in Percutaneous Coronary Intervention(PCI)

Stent Fractures after Superficial Femoral Artery Stenting

Risk prediction of in-stent restenosis among patients with coronary drug-eluting stents: current clinical approaches and challenges

Translational research on novel drug-eluting stents in percutaneous coronary intervention

Drug Eluting Stents in Renal Functional Insufficiency Patients and Its Influence on Stent Thrombosis.

Evaluation and management of drug-eluting stent in-stent restenosis

New Drug-Eluting Stent Technologies

Coexistent In-Stent Restenosis, Late Incomplete Stent Apposition and Mural Thrombus in a Zotarolimus-Eluting Stent.